Department Blog

Posted 12/20/2019 by Deborah Stein

Survival Associated With Sirolimus Plus Tacrolimus Maintenance Without Induction Therapy Compared With Standard Immunosuppression After Lung Transplant

Jon Mark Hirshon, MD, MPH, FACEP, FAAEM, FACPM, Professor, Department of Emergency Medicine, is among the authors of the article, “Survival Associated With Sirolimus Plus Tacrolimus Maintenance Without Induction Therapy Compared With Standard Immunosuppression After Lung Transplant” (full text available) published in JAMA Network Open. Their objective was to compare survival between patients receiving sirolimus plus tacrolimus vs mycophenolate mofetil plus tacrolimus (the most common maintenance therapy) and to identify the combination of induction and maintenance therapy associated with the highest survival. They found that sirolimus plus tacrolimus was associated with improved patient survival after lung transplant compared with mycophenolate mofetil plus tacrolimus, and that no antibody induction therapy with sirolimus plus tacrolimus was associated with maximal survival.